Table 2.
Clinical trials on TAM-targeted therapy from CDE database
| Trial ID | Mechanisms | Drugs | Tumors | Trial Phase | Trial status | Started year | Combination status |
|---|---|---|---|---|---|---|---|
| CTR20150824 | CSF-1/CSF-1R | Sulfatinib | thyroid carcinoma | II | completed | 2015 | monotherapy |
| CTR20160572 | Sulfatinib | biliary tract carcinoma | II | completed | 2016 | monotherapy | |
| CTR20150737 | Sulfatinib | pancreatic neuroendocrine | III | open | 2015 | monotherapy | |
| CTR20160448 | PLX3397 | melanoma | I/II | terminated | 2016 | monotherapy | |
| CTR20170936 | chiauranib | hepatocellular carcinoma | I | completed | 2017 | monotherapy | |
| CTR20170246 | chiauranib | non-Hodgkin’s lymphoma | I | completed | 2017 | monotherapy | |
| CTR20170765 | chiauranib | small cell lung cancer | I | open | 2017 | monotherapy | |
| CTR20170767 | chiauranib | ovarian cancer | I | completed | 2017 | monotherapy | |
| CTR20190609 | chiauranib | ovarian cancer | II | completed | 2019 | chemotherapy | |
| CTR20210658 | chiauranib | small-cell lung cancer | III | open | 2021 | monotherapy | |
| CTR20171427 | CM082 | gastric cancer | I | open | 2017 | chemotherapy | |
| CTR20160487 | CM082 | acute myeloid leukemia | I | open | 2016 | monotherapy | |
| CTR20210743 | ABSK021 | advanced solid tumor | I | open | 2021 | monotherapy | |
| CTR20201034 | surufatinib | advanced solid tumor | I | open | 2020 | PD-1 inhibitor | |
| CTR20181945 | surufatinib | biliary tract carcinoma | II/III | open | 2018 | monotherapy | |
| CTR20132583 | CXCL12/CXCR4 | plerixafor | non-Hodgkin’s lymphoma | III | completed | 2014 | chemotherapy |
| CTR20130291 | Burixafor | acute myeloid leukemia | I | completed | 2016 | chemotherapy | |
| CTR20200132 | PI3Kγ signal pathway | Duvelisib | follicular lymphoma | II | open | 2020 | monotherapy |
| CTR20182057 | CT365 | advanced solid tumor | I | open | 2018 | monotherapy | |
| CTR20200204 | TLR7 | TQ-A3334 | non-small cell lung cancer | I | open | 2020 | monotherapy |
| CTR20201728 | TLR8 | DN1508052-01 | advanced solid tumors | I | open | 2020 | monotherapy |
| CTR20192522 | CD47/SIRPα pathway | TJ011133 | acute myeloid leukemia | I/II | open | 2019 | chemotherapy |
| CTR20210555 | TJ011133 | acute myeloid leukemia | I/II | open | 2021 | chemotherapy | |
| CTR20192612 | IMM0306 | non-Hodgkin’s lymphoma | I | open | 2020 | monotherapy | |
| CTR20181964 | SHR-1603 | advanced solid tumor | I | terminated | 2018 | monotherapy | |
| CTR20200175 | IBI322 | advanced malignant tumors | I | open | 2020 | monotherapy | |
| CTR20191531 | IMM01 | lymphoma | I | open | 2019 | monotherapy | |
| CTR20202684 | AK117 | advanced solid tumors/lymphomas | I | open | 2020 | monotherapy | |
| CTR20200938 | IBI188 | acute myeloid leukemia | I | open | 2020 | chemotherapy | |
| CTR20210761 | IBI188 | advanced malignant tumors | I | open | 2021 | PD-1 inhibitor chemotherapy |